EGFR mutation analysis in non-small-cell lung cancer: Experience from routine diagnostics;EGFR-Mutationsanalyse beim nichtkleinzelligen Lungenkarzinom: Erfahrungen aus der Routinediagnostik

Pathologe

Volumn 30, Issue 5, 2009, Pages 384-392

  Tapia, C ^a   Savic, S ^a   Bihl, M ^a   Rufle, A ^a   Zlobec, I ^a   Terracciano, L ^a   Bubendorf, L ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

EGFR; Lung cancer; Mutation; Non small cell lung cancer; TTF 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

ADENOCARCINOMA; ARTICLE; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; TUMOR BIOPSY;

ADENOCARCINOMA; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME DELETION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EQUIPMENT DESIGN; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MICRODISSECTION; MICROSCOPY, CONFOCAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS;

EID: 70249092148     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-009-1141-4     Document Type: Article

References (30)

1. Bilello KS, Murin S, Matthay RA (2002) Epidemiology, etiology and prevention of lung cancer. Clin Chest Med 23:1-25
2. Boldrini L, Gisfredi S, Ursino S et al (2007) Mutatio-nal analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2:1086-1090
3. Ciardiello F,Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
4. Crino L, Foglietta J, Hamzaj A (2007) Lung cancer. J Thorac Oncol 2:S24-S26
5. D'addario G, Rauch D, Stupp R et al (2008) Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced nson-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19:739-745
6. Eberhard DA, Giaccone G, Johnson BE (2008) Bio-markers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26:983-994
7. Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909
8. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043
9. Grossi F, Aita M, Follador A et al (2007) Sequential, alternating and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12:451-464
10. Janne PA (2008) Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 60 (Suppl 2):S3-S9
11. Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21 (Suppl 2):S16-S22
12. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
13. Marchetti A, Felicioni L, Buttitta F (2006) Assessing EGFR mutations. N Engl J Med 354:526-528
14. Missero C, Pirro MT, Di Lauro R (2000) Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1. Mol Cell Biol 20:2783-2793
15. Murray S,Timotheadou E, Linardou H etal (2006) Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clini-copathological features in non-small cell lung cancer patients. Lung Cancer 52:225-233
16. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
17. Riely GJ (2008) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 3:S146-S149
18. Savic S, Tapia C, Grilli B et al (2008) Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 98:154-160
19. Schutze K, NiyazY, Stich M et al (2007) Noncont-act laser microdissection and catapulting for pure sample capture. Methods Cell Biol 82:649-673
20. Sequist LV, Bell DW, Lynch TJ et al (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595
21. Sharma SV, Bell DW, Settleman J et al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181
22. Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346 (Pubitemid 40425952)
23. Smith GD, Chadwick BE, Willmore-Payne C et al (2008) Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 61:487-493
24. Tsao AS, Tang XM, Sabloff B et al (2006)Clinicopa-thologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 1:231-239
25. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-144
26. Yamamoto H, Toyooka S, Mitsudomi T (2008) Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 315-321
27. Yatabe Y, Kosaka T, Takahashi T et al (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29:633-639
28. Yatabe Y, Takahashi T, Mitsudomi T (2008) Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68:2106-2111
29. Zhang X, Chang A (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5:209-217
30. Zhu CQ, Da Cunha Santos G, Ding Ket al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:4268-4275